AbbVie rises on profit forecast lift, upbeat quarter
Shares of drugmaker AbbVie ABBV.N rise 2.7% to $185.3 premarket
AbbVie raises its 2025 profit forecast after better-than-expected sales of its newer immunology drugs Skyrizi and Rinvoq help it beat quarterly earnings expectations
Company expects its annual adjusted profit to be between $12.09 and $12.29 per share, up from its previous estimate of $11.99 to $12.19
ABBV earns adj. Q1 profit of $2.46 per share, compared with analysts' average expectation of $2.38
As of last close, ABBV had risen 1.5% YTD
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Recommended Articles
Featured Tools
Top News
AMD Q1 Earnings: Data Center Revenue Surges 57% Driving Results Above Estimates, Shares Rise Over 16% After Hours

Micron Stock Forecast: Can the AI Memory Super-Cycle Drive MU to $3,000 by 2030?

Dell Stock Analysis: Is It Still Undervalued and the Best AI Infrastructure Play by 2026?

Meta Stock Price Forecast 2026-2030: Can META Hit $1,000?

Vanguard ETF Could Beat the S&P 500 Again in 2026 —— Why Investors Are Paying Attention

Tradingkey







